DRUG-INDUCED PARKINSONISM IN THE AGED - RECOGNITION AND PREVENTION

被引:30
作者
GERSHANIK, OS
机构
[1] Seccion Enfermedades Extrapiramidales, Centro Neurologico-Hospital Frances, Buenos Aires
关键词
D O I
10.2165/00002512-199405020-00006
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Drug-induced Parkinsonism is a frequent adverse effect of numerous drugs interfering with dopamine function at the basal ganglionic level. It accounts for 4% of all patients with Parkinsonism seen in neurology clinics. Pharmacological agents implicated in the production of this disorder have a wide range of applications in medicine, beyond the treatment of psychiatric illnesses. Antipsychotics, substituted benzamides and calcium channel blockers are the drugs most commonly involved. The aged population is at an increased risk of drug-induced Parkinsonism due to intrinsic factors and because they often receive multiple drugs, including those from self-medication. Lack of knowledge in the medical profession of the potential hazards involved in the use of certain drugs plays a contributory role in the development of drug-induced Parkinsonism. Physicians should be always alert in order to detect, as early as possible, the presence of extrapyramidal symptoms in patients exposed to medications with antidopaminergic properties. Whenever possible, withdrawal of the medication will help resolve symptoms; complete remission takes place within 6 to 18 months in the majority of patients. The use of anti-Parkinsonian drugs is only advisable if the symptomatology is disabling. The best available treatment is prevention.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 22 条
[1]   A SURVEY OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS [J].
AYD, FJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1961, 175 (12) :1054-&
[2]   5-HT2 ANTAGONIST RITANSERIN IN NEUROLEPTIC-INDUCED PARKINSONISM - A DOUBLE-BLIND COMPARISON WITH ORPHENADRINE AND PLACEBO [J].
BERSANI, G ;
GRISPINI, A ;
MARINI, S ;
PASINI, A ;
VALDUCCI, M ;
CIANI, N .
CLINICAL NEUROPHARMACOLOGY, 1990, 13 (06) :500-506
[3]   COMPARISON OF THE INVITRO RECEPTOR SELECTIVITY OF SUBSTITUTED BENZAMIDE DRUGS FOR BRAIN NEUROTRANSMITTER RECEPTORS [J].
CHIVERS, JK ;
GOMMEREN, W ;
LEYSEN, JE ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1988, 40 (06) :415-421
[4]  
CHOUZA C, 1986, LANCET, V1, P1303
[5]  
DELAY J, 1952, Ann Med Psychol (Paris), V110, P112
[6]   PARKINSONISM ASSOCIATED WITH CALCIUM-CHANNEL BLOCKERS - A PROSPECTIVE FOLLOW-UP-STUDY [J].
GARCIARUIZ, PJ ;
DEYEBENES, JG ;
JIMENEZJIMENEZ, FJ ;
VAZQUEZ, A ;
URRA, DG ;
MORALES, B .
CLINICAL NEUROPHARMACOLOGY, 1992, 15 (01) :19-26
[7]  
GERSHANIK OS, 1993, CURR OPIN NEUROL NEU, V6, P369
[8]   TETRABENAZINE THERAPY OF DYSTONIA, CHOREA, TICS, AND OTHER DYSKINESIAS [J].
JANKOVIC, J ;
ORMAN, J .
NEUROLOGY, 1988, 38 (03) :391-394
[9]  
LAPORTE JR, 1986, LANCET, V2, P853
[10]  
MARTIMASSO JF, 1988, 9TH INT S PARK DIS, P137